The company’s application for a Eurostars grant comprising the development of a treatment for diabetes has been approved.

Follicum is the coordinator of the project. Other partners include Lund University, Bioassay Labor für biologische Analytik GmbH and Deutsche Diabetes-Forschungsgesellschaft (DDZ).

Additional resources for the company’s development of a peptide-based treatment of diabetes

The grant comprising just under EUR 0.7 M commences December 1, 2019 and provides additional resources for the company’s development of a peptide-based treatment of diabetes. Follicum, together with other partners in the consortium, will study Follicum’s peptides and their ability to induce insulin secretion, while protecting and preserving pancreatic cells and preventing diabetic complications. The project will also conduct the preclinical studies necessary for laying the foundation for a new candidate drug for the treatment of diabetes and its serious complications. These activities enable subsequent GMP production, safety studies and clinical validation.

“We are delighted to have received the announcement that our application has been granted and we can now, with greater focus, develop our drug candidate in diabetes into a first-in-class treatment that can benefit patients. The partners in the consortium are all reputable and leading in their respective research fields, and we look forward to collaborating in this project,” says Jan Alenfall, CEO, Follicum.